The present application is related to, claims the earliest available effective filing date(s) from (e.g., claims earliest available priority dates for other than provisional patent applications; claims benefits under 35 USC §119(e) for provisional patent applications), and incorporates by reference in its entirety all subject matter of the following listed applications; the present application also claims the earliest available effective filing date(s) from, and also incorporates by reference in its entirety all subject matter of any and all parent, grandparent, great-grandparent, etc. applications of the following listed applications:
The present application relates, in general, to endoprosthetic devices for the treatment and/or management of disease, disorders, or conditions.
In one aspect, a device includes but is not limited to: a flexible hollow portion with an outer surface and an inner surface and wherein the flexible hollow portion is sized for placement in a location in a receiver; and a plurality of movable parts coupled to the inner surface of the flexible hollow portion, the movable parts operable as a group for moving particles. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present application.
In one aspect, a method includes but is not limited to: forming a supporting passage implantable in an animal; coupling a plurality of moving parts to the supporting passage; and sizing the supporting passage and the plurality of moving parts coupled to the supporting passage for placement in a location in the animal. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present application.
In one aspect, a method includes but is not limited to: placing a hollow expandable device in a luminal portion of a recipient wherein the interior of the hollow expandable device is coupled to a plurality of moving pieces; positioning the hollow expandable device in the lumen of the organ; and monitoring the hollow expandable device. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present application.
In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.
In one or more various aspects, related systems include but are not limited to energy- and power-management circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.
In addition to the foregoing, various other method and or system aspects are set forth and described in the text (e.g., claims and/or detailed description) and/or drawings of the present application.
The foregoing is a summary and thus contains, by necessity; simplifications, generalizations and omissions of detail; consequently, those skilled in the art will appreciate that the summary is illustrative only and is NOT intended to be in any way limiting. Other aspects, inventive features, and advantages of the devices and/or processes described herein, as defined solely by the claims, will become apparent in the non-limiting detailed description set forth herein.
The use of the same symbols in different drawings typically indicates similar or identical items.
The present application uses formal outline headings for clarity of presentation. However, it is to be understood that the outline headings are for presentation purposes, and that different types of subject matter may be discussed throughout the application (e.g., device(s)/structure(s) may be described under the process(es)/operations heading(s) and/or process(es)/operations may be discussed under structure(s)/process(es) headings). Hence, the use of the formal outline headings is not intended to be in any way limiting.
1. A Ciliated Stent-Like System(s) and/or Process(es).
With reference now to
It will also be appreciated by those skilled in the art that in one embodiment, the ciliated stent-like system includes a powered ciliated stent-like system. Furthermore, while the structure is referred to as a ciliated stent-like system, the terminology is not intended to be limiting. The term stent-like system may for example, refer stents or similar devices that may include any structure or device for providing support to an orifice, such as, for example, slender rods, threads, or catheters.
A. Structure(s) and or Device(s)
With reference to the figures, and with reference now to
With reference to the figures, and with reference now to
Continuing to refer to
Some or all of the parts, for example, the tissue-contacting parts, of the ciliated stent-like system 100 may be formed from a biocompatible material, a shape memory material or a metal such as, for example, nickel titanium alloy, metal, silicon, plastic or polymer. Examples of polymers include but are not limited to, polyethylene, polypropylene, polyglycolic acid, polylactic acid, cellulose acetate, or cellulose nitrate. In one aspect some or all of the parts of the ciliated stent-like system 100 may be made of a biodegradable material. In another aspect, the ciliated stent-like system 100 may be coated by one or more polymers or materials which are, for example, biocompatible, organic or biodegradable.
Furthermore, the ciliated stent-like system 100 may be used to deliver an agent, for example, including but not limited to, by passive delivery or under control of an controller either internal or external to the ciliated stent-like system 100. In one aspect, when delivering the agent by passive delivery, the ciliated stent-like system 100 may be coated with one or more agents, such as, for example, including, but not limited to, a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, or a peptide.
In one aspect the ciliated stent-like system 100 is sized for placement in the recipient, for example, including but not limited to, in a lumen of a blood vessel in an adult human body. In another aspect the ciliated stent-like system 100 is sized for placement, for example, in the lumen of an organ in a pediatric body. In one example, the size of the diameter of the stent may be about 1-2 cm. In another example, both of the exterior and the interior diameters of the ciliated stent-like system 100 may be uniform or may vary to accommodate dimensions of the location of insertion, placement of functionality-conferring devices, or functionality of the ciliated stent-like system 100. In another example, the ciliated stent-like system 100 may be sized to fit within a portion of a bronchial tree, wherein the internal diameter of portions of the bronchial tree is about 0.1-10 mm. It is also within the scope of the invention, that the ciliated stent-like system 100 may be used to replace, fully or partially, the functionality of the section portion of the bronchial tree. In this example, the outer diameter of the ciliated stent-like system 100 has a diameter corresponding to about the external diameter of the portion of the bronchial tree.
With reference now to
In one aspect, the ciliated stent-like system 100 has a plurality of cilia 320 and 321 arranged in the inner surface 311 of the ciliated stent-like system 100. The plurality of cilia may include one or more movable parts attached to the ciliated stent-like system 100. In one aspect, the plurality of cilia 320 and 321 may be arranged, for example, in rows, columns, or similarly-ordered groupings. The plurality of cilia 320 and 321 may fully or partially encompass the inner surface 311. In one aspect, the length, the dimensions or other configuration aspects of the cilia will depend on the intended functions of the cilia. For example, where a pulmonary ciliated stent is employed in a trachea or a bronchi, the ciliary movement may help degrade occlusions or the formation thereof. In this example, the cilia may be long, the undulatory movement of the cilia may be responsible for moving, expelling or propelling, for example, fluid, clots, occlusive material, or fluid, particles, fluidized particles, mucus, exudate or biological debris. In another aspect, the plurality of cilia 320 and 321, may be a combination of various ciliary lengths suitable for operating an undulating propelling mechanism. It will be appreciated by those skilled in the art that the plurality of cilia 320 and 321 includes, but is not limited to, cilia-like functional structures and/or cilia-like appearing structures.
In one aspect the plurality of cilia 320 and 321 may be arranged on the inner surface 311 of the ciliated stent-like system 100. However, it is within the scope of the invention to include the plurality of cilia 320 and 321 on the outer surface 312 or on both surfaces. It is also within the scope of the invention, that the plurality of cilia 320 and 321 present on the outer surface 312 or the inner surface 311 may differ, for example, in the type of cilia, control mechanism associated with the cilia, and/or the function performed by the plurality of cilia 320 and 321. For example, the plurality of cilia 320 and 321 present on the outer surface 311 may be of a type, or have features that aid in the placement of the ciliated stent-like system 100 in a location in a recipient whereas the plurality of cilia 320 and 321 present on the inner surface 312 may be of a type or have features that perform other functions.
With reference now to
Ciliary movement may be self-propagating or induced. For example, with regards to a pulmonary ciliated stent, induction may occur when a particle touches a cilium, or when the patient coughs, or otherwise moves or actuates his/her chest. Actuation may make use of stored energy, derived, for example, from previous motion; in the pulmonary case, for example, this motion may be that associated with inhalation and/or exhalation or with myocardial motion. The ciliated stent-like system 100 may be part of a disposable stent, for example, where the majority of the stent is composed of biodegradable or other material subject to solubilization or disintegration within the body. It will be appreciated by those skilled in the art that techniques for fabricating such cilia from self-oscillating polymer gels are well known in and are herein incorporated by reference. It will also be appreciated by those skilled in the art that techniques for favoring ciliary-driven transport in one direction along the stent relative to the other, particularly when a power source is available, are well-known and are herein incorporated by reference.
In another aspect, the plurality of cilia 310 and 321 includes one or more flexible polymeric rods. Additional information may be found in a presentation by R. L. Carroll, B. Wilde, R. M. Taylor, L. Vicci, S. Washburn, and R. Superfine, “Biomimetic Flexible Polymer Rods—Artificial Cilia.” The 70th Annual meeting of the Southeastern Section of the American Physical Society, Nov. 6-8, 2003. Polymeric rods imitating ciliary structures are known structures. The polymeric rods may have a length about 10 microns, and a diameter of about 800 nm and would be able to propel fluid, fluidized particles, mucus, exudate or biological debris. However, polymeric rods of different dimensions are within the scope of the invention. In one example, the one or more flexible polymeric rods includes magnetic material. External oscillating magnetic fields may manipulate or actuate the flexible polymeric fields, for example, directly or by inductive coupling to an energy-store and/or power supply within the stent. It will be appreciated by those skilled in the art that such techniques and similar techniques are known, and are herein incorporated by reference.
In another aspect, the plurality of cilia 320 and 321 includes one or more MEMS micro-actuator arrays. It will be appreciated by those skilled in the art that the one or more MEMS micro-actuator arrays may be made to perform various modes of oscillatory movement and could be included in the interior of the ciliated stent-like system 100, for example, to provide a force for moving fluid, particles, fluidized particles, mucus, exudate or biological debris through the interior of the ciliated stent-like system 100. It will be appreciated by those skilled in the art that MEMS fabrication and actuation techniques are known in the art, and are herein incorporated by reference.
With reference now to the
In one aspect, the plurality of cilia 310 and 321 or the array 620 includes one or more actuator arrays, for example, MEMS actuator arrays. The MEMS actuator arrays may be coated with a thin film of a material that improves the physical, chemical, or electronic, properties of the array, for example, including, but not limited to, polyimide. The MEMS actuator arrays may promote the sensorless manipulation of small objects using thermal and electrostatic control mechanisms. In one aspect the MEMS actuator arrays may be arranged, for example, including but not limited to, on the inner surface 311 of the ciliated stent-like system 100. The actuator arrays may be capable of providing a wide variety of movements, such as, for example, translation, rotation, centering, or orientation. Additionally, they may induce a low-level gait to the plurality of cilia 320 and 321, such as, for example, up-and-down motion, cyclical motion, or flagelatory motion resulting in the fluid, particles, fluidized particles, mucus, exudate or biological debris, being moved. In this example, the speed of the moving fluid, particles, fluidized particles, mucus, exudate or biological debris is dependant on the displacement of the actuators per cycle, the number of times the cycle is repeated per unit of time, the surface properties of the particle to be moved, the weight of the particle to be moved, the local surface tension, the local orientation relative to the direction of gravity or other acceleration field, etc. In another example, the one or more MEMS actuator arrays may be used to induce a high-level control, or a high-level gait, such as, for example, orienting and aligning fluid, particles, fluidized particles, mucus, exudate or biological debris. In this example, the one or more MEMS actuator arrays may be used to position or rotate an obstructing or blocking particle for its expulsion or removal from the lumen of a vessel. It will be appreciated by those skilled in the art that such techniques are known in the art and are herein incorporated by reference. Additional information may be found in an article by W. Suh, R. B. Darling, K. F. Böhringer, B. R. Donald, H. Baltes, G. T. A. Kovacs, “Fully Programmable MEMS Ciliary Actuator Arrays for Micromanipulation Tasks.” IEEE International Conference on Robotics and Automation (ICRA), pp. 1101-1108, San Francisco, Calif., April 2000, which is herein incorporated by reference.
Continuing to refer to
In another aspect, motors may be included in the plurality of cilia 320 and 321 to provide the energy or to generate the force needed for moving fluid, particles, fluidized particles, mucus, exudate or biological debris or fluid. In one example, protein molecule-based motors, such as those employing kinesin or dynein, may be used to provide motive force for ciliary rotational or directional movement. For example, including but not limited to, the direction of the movement of the biological molecular motors, is influenced by the orientation of any tubulin present, or the matrix that the motors may use as their tracks. In one aspect, ATP hydrolysis may provide the energy for the actuation of the biological molecular motors, and ATP and ATPase may be furnished, for example, by coupling mitochondria to the biological molecular motors. In another example, the actin-myosin system may be included in the plurality of cilia 320 and 321 in order to provide the force for moving fluid, particles, fluidized particles, mucus, exudate or biological debris. It will be appreciated by those skilled in the art that such techniques are known in the art and are herein incorporated by reference. This subject is described in further detail by N. Thomas and R. A. Thornhill in the Journal of Physics D: Applied Physics 31, pages 253-266, 7 Feb. 1998, and by Carlo Montemagno, George Bachand, Scott Stelick, and Marlene Bachand in Nanotechnology 10:225-231, 1999, both of which are herein incorporated by reference.
In another aspect, the plurality of cilia 320 and 321 includes an electro-active transducer with an electroactive polymer, which deflects in response to an electrical field. In one example, the deflection of the electroactive polymer is operable to move fluid. In another example, the deflection of the electroactive polymer is operable to move fluid, particles, fluidized particles, mucus, exudate or biological debris, such as, for example, congealed or clotted liquids. The transducer includes at least two electrodes in electrical communication with the electroactive polymer. Deflection of the electroactive polymer may produce a range of motions, including, but not limited to, one or more of a rotational, vibrational, linear, flagelatory or the like. Additional information regarding electroactive polymers can be found in U.S. Patent Application No. 2004/0008853 which is herein incorporated by reference.
In another aspect, the plurality of cilia 320 and 321 includes, for example, electrostrictive materials, such as, piezoelectric materials, or magnetostrictive materials. These materials may be actuated by application of electric or magnetic fields, respectively, sourced, for example, by a power source internal or external to the ciliated stent-like system 100. In one aspect, the power source may be external to the ciliated stent-like system 100 but internal to the recipient. For example, including, but not limited to, acoustic energy may be sourced from either within the ciliated stent-like system 100, from elsewhere within the recipient in which the ciliated stent-like system 100 is located. In another aspect, the power source may be external to the recipient, for example, power may be supplied to the ciliated stent-like system 100 from outside of the recipient, including powering actuation of the plurality of cilia 320 and 321, either directly or indirectly. In yet another aspect, the power source may be internal to the ciliated stent-like system 100.
In another aspect, control of ciliary motion may be performed by a controller, for example, including, but not limited to, one centered on a digital microprocessor, embedded in whole or in part within the ciliated stent-like system 100 or the powered stent-like system. Such embedded controller may be interrogated or programmed with acoustic-, wired- or optical-circuitry or via wireless transmission of electrically-, magnetically- or electromagnetically-conveyed signals. Such controller may be informed by one or more sensors within the ciliated stent-like system 100 or the powered stent-like system. Such controller may, from time-to-time in a programmed manner, also direct release of one or more materials from one or more reservoirs or storage compartments located within the ciliated stent-like system 100 or the powered stent-like system, or may direct, monitor or control one or more large-scale motions of part or all of the ciliated stent-like system 100 or the powered stent-like system system 100.
Provision of energy to the power the ciliated stent-like system 100 includes, but is not limited to, including one or more primary or secondary batteries possibly embedded into, battery-recharging or direct power transfer via body-external magnetic, electric, acoustic, gross-mechanical-motion or optical fields applied for this purpose, a system generating chemical energy possibly embedded within the system. In one aspect, energy may be recharged or regenerated. For example, by external or intra-body sources, and transduction/conversion of kinetic energy deriving from action of one or more muscles of the body in which the ciliated stent-like system 100 or the powered stent-like system is embedded or implanted, for example, including but not limited to, inertial-mechanical-electrical transduction.
The ciliated stent-like system 100 or the powered stent-like system may include additional devices, integrated devices, or properties for diametrically expanding and/or contracting, as well as translating along the axis of the local lumen, any portion of the system, including all of it. These may include, but aren't limited to, mechanical devices, such as, for example, linear motors, electro- or magneto-strictive actuators, tractive devices, pneumatic actuators, peristaltic devices, etc.
The ciliated stent-like system 100 or the powered stent-like may include additional devices, integrated devices, or properties for sensing and/or quantitatively measuring to a specified accuracy one or more features or variables of its environment, for processing, storing and transmitting such information to a body-external receiver, and for receiving control or interrogation information from one or more body-external points.
The format of materials which may be stored and/or released by the ciliated stent-like system 100 includes, but is not limited to, liquids, gases, emulsions, gels, mists, sprays, dusts, powders, aerosolized or carbureted particulate matter of all types, and the composition thereof may be one or more of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, or a peptide, a contrast agent, or a pharmacological agent.
B. Operation(s) and/or Process(es)
With reference to the figures, and with reference now to
In one implementation, the ciliated stent-like system 100 includes, but is not limited to, an external controller for manipulating the ciliated stent-like system 100 and/or the plurality of cilia 320 and 321. Manipulation of the ciliated stent-like system 100 may include, for example, expelling, moving, guiding, positioning or repositioning the ciliated stent-like system 100. In one example, the ciliated stent-like system 100 may be controlled or manipulated from a remote location by medical personnel. In another example, the ciliated stent-like system 100 may be controlled or manipulated external to the recipient. In another implementation, the external controller may include a monitoring system, and/or wireless circuitry for manipulating the ciliated stent-like system 1000 and/or the plurality of cilia 320 and 321.
In one implementation, the ciliated stent-like system 100 includes a system or apparatus for removing or relocating biological debris of various types, such as, for example, fluid, particles, fluidized particles, mucus, exudate or biological debris. For example, the apparatus or the system may include a siphon connected to a monitor for visualizing the debris field. Observable debris may then be siphoned by positioning and operating the siphon. In one example, the siphon may be used in collaboration with the plurality of cilia 320 and 321. In this example, the plurality of cilia 320 and 321 may be used to gather and/or expel any debris and the siphon employed to collect and/or relocate the gathered or expelled debris, for example, from within one or more locations in the pulmonary tract into the esophagus.
In one implementation, the use of the ciliated stent-like system 100 includes, but is not limited to, the treatment of pulmonary diseases, such as, for example, chronic obstructive pulmonary disease (COPD). COPD includes diseases characterized by dyspnea or disorders characterized by, such as, for example, chronic bronchitis, asthma, or emphysema. Additional information may be found in the following two articles by P. J. Barnes, “Small Airways in COPD.” New England Journal of Medicine, 350:256, pages 2635-2637, Jul. 04, 2004, and by E. R. Sutherland, R. M. Cherniack, “Management of Chronic Obstructive Pulmonary Disease”, pages 2689-2697, Jun. 24, 2004, which is herein incorporated by reference. In another implantation, the ciliated stent-like system 100 may be configured to address diseases, such as, for example, cystic fibrosis, in which under-performance of the muco-ciliary system results in the accumulation of mucus, exudates and pathogens in the lung, causing prolonged, occasionally life-threatening infections. In this example, the ciliated stent-like system 100 may be employed to help clear the air passages by expelling actively, for example, fluid, fluidized particles, mucus, exudate or biological debris, including in conjunction with release and/or dispersal of surfactants or viscosity-modulating agents, either from the ciliated stent-like system 100 or from other sources.
In one implementation, the plurality of cilia 320 and 321 are programmed for moving intermittently. In another implementation, the plurality of cilia 320 and 321 may be programmed to move continuously. It will be appreciated by those skilled in the art that the movements of the plurality of cilia 320 and 321 may be adjusted depending on a number of criteria, for example, the area of use or the specifics of the task required to be performed.
C. Variation(s), and/or Implementation(s)
Those having skill in the art will recognize that the present application teaches modifications of the devices, structures, and/or processes within the spirit of the teaching herein. For example, the ciliated stent-like system 100 need not be limited to a cylindrical or tubular shape. For example, the ciliated stent-like system 100 may have a composite or multi-segmented flexible shape to provide a best fit in the use-location in the animal. In another example, the ciliated stent-like system 100 may have a substantially planar or conical shape, or may change its shape markedly as it installs within or transverses a luminal tract of a vessel within an animal. Other modifications of the subject matter herein will be appreciated by one of skill in the art in light of the teachings herein.
It will also be appreciated by those skilled in the art that the ciliated stent-like system 100 may be made of materials that render it fully or partially disposable. In one example, the outer surface 312 of the ciliated stent-like system 100 is designed to deliver an agent or perform functions to remove an obstruction, and then disintegrate. For example, the outer surface 312 of the ciliated stent-like system 100 may be coated with the agent which is made to contact the walls of the lumen. The main body of the ciliated stent-like system 100 may be designed to disintegrate or dissolve over a certain interval of time leaving the agent on/within the lumen. Alternatively, the ciliated stent-like system 100 may release one or more agents into the lumen itself, either continually or under program control. Any such agent may be replenished by reloading into a compartment or reservoir within the ciliated stent-like system 100. Other modifications of the subject matter herein will be appreciated by one of skill in the art in light of the teachings herein.
It will also be appreciated by those skilled in the art that the ciliated stent-like system 100 may include wireless or robotic attachments for controlling it from the exterior of the recipient or animal in which it is placed. Other modifications of the subject matter herein will be appreciated by one of skill in the art in light of the teachings herein.
The foregoing described aspects depict different components contained within, or connected with, different other components. It is to be understood that such depicted architectures are merely exemplary, and that in fact many other architectures can be implemented which achieve the same functionality. In a conceptual sense, any arrangement of components to achieve the same functionality is effectively “associated” such that the desired functionality is achieved. Hence, any two components herein combined to achieve a particular functionality can be seen as “associated with” each other such that the desired functionality is achieved, irrespective of architectures or intermedial components. Likewise, any two components so associated can also be viewed as being “operably connected”, or “operably coupled”, to each other to achieve the desired functionality.
While particular aspects of the present subject matter described herein have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this subject matter described herein and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this subject matter described herein. Furthermore, it is to be understood that the invention is defined solely by the appended claims. It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to inventions containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations), etc.
Number | Name | Date | Kind |
---|---|---|---|
3391697 | Greatbatch | Jul 1968 | A |
3821469 | Whetstone et al. | Jun 1974 | A |
3837339 | Aisenberg et al. | Sep 1974 | A |
3941127 | Froning | Mar 1976 | A |
3983474 | Kuipers | Sep 1976 | A |
4054881 | Raab | Oct 1977 | A |
4119900 | Kremnitz | Oct 1978 | A |
4202349 | Jones | May 1980 | A |
4262306 | Renner | Apr 1981 | A |
4314251 | Raab | Feb 1982 | A |
4317078 | Weed et al. | Feb 1982 | A |
4339953 | Iwasaki | Jul 1982 | A |
4367741 | Michaels | Jan 1983 | A |
4396885 | Constant | Aug 1983 | A |
4403321 | Krüger | Sep 1983 | A |
4418422 | Richter et al. | Nov 1983 | A |
4431005 | McCormick | Feb 1984 | A |
4583190 | Salb | Apr 1986 | A |
4585652 | Miller et al. | Apr 1986 | A |
4628928 | Lowell | Dec 1986 | A |
4638798 | Shelden et al. | Jan 1987 | A |
4642786 | Hansen | Feb 1987 | A |
4651732 | Frederick | Mar 1987 | A |
4658214 | Petersen | Apr 1987 | A |
4714460 | Calderon | Dec 1987 | A |
4717381 | Papantonakos | Jan 1988 | A |
4733661 | Palestrant | Mar 1988 | A |
4763667 | Manzo | Aug 1988 | A |
4769006 | Papantonakos | Sep 1988 | A |
4771772 | DeWitt | Sep 1988 | A |
4800898 | Hess et al. | Jan 1989 | A |
4805615 | Carol | Feb 1989 | A |
4817601 | Roth et al. | Apr 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4889526 | Rauscher et al. | Dec 1989 | A |
4905689 | Stack et al. | Mar 1990 | A |
4943296 | Funakubo et al. | Jul 1990 | A |
4944659 | Labbe et al. | Jul 1990 | A |
4962453 | Pong et al. | Oct 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5019372 | Folkman et al. | May 1991 | A |
5031109 | Gloton | Jul 1991 | A |
5051906 | Evans, Jr. et al. | Sep 1991 | A |
5078140 | Kwoh | Jan 1992 | A |
5086401 | Glassman et al. | Feb 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5165064 | Mattaboni | Nov 1992 | A |
5176638 | Michael | Jan 1993 | A |
5188111 | Yates et al. | Feb 1993 | A |
5204814 | Noonan et al. | Apr 1993 | A |
5234457 | Andersen | Aug 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5279607 | Schentag et al. | Jan 1994 | A |
5310404 | Gyory et al. | May 1994 | A |
5313835 | Dunn | May 1994 | A |
5314451 | Mulier | May 1994 | A |
5321614 | Ashworth | Jun 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5337732 | Grundfest et al. | Aug 1994 | A |
5338625 | Bates et al. | Aug 1994 | A |
5339051 | Koehler et al. | Aug 1994 | A |
5353807 | DeMarco | Oct 1994 | A |
5374285 | Vaiani et al. | Dec 1994 | A |
5381786 | Spears | Jan 1995 | A |
5386741 | Rennex | Feb 1995 | A |
5395390 | Simon et al. | Mar 1995 | A |
5398670 | Ortiz et al. | Mar 1995 | A |
5403311 | Abele et al. | Apr 1995 | A |
5411551 | Winston et al. | May 1995 | A |
5437660 | Johnson et al. | Aug 1995 | A |
5476450 | Ruggio | Dec 1995 | A |
5497147 | Arms et al. | Mar 1996 | A |
5502638 | Takenaka | Mar 1996 | A |
5507287 | Palcic et al. | Apr 1996 | A |
5522394 | Zurbrugg | Jun 1996 | A |
5551953 | Lattin et al. | Sep 1996 | A |
5554914 | Miyazawa | Sep 1996 | A |
5569968 | Lal et al. | Oct 1996 | A |
5574347 | Neubauer | Nov 1996 | A |
5589932 | Garcia-Rubio et al. | Dec 1996 | A |
5593434 | Williams | Jan 1997 | A |
5599324 | McAlister et al. | Feb 1997 | A |
5610488 | Miyazawa | Mar 1997 | A |
5624398 | Smith et al. | Apr 1997 | A |
5632754 | Farley et al. | May 1997 | A |
5643296 | Hundertmark et al. | Jul 1997 | A |
5662587 | Grundfest et al. | Sep 1997 | A |
5669874 | Feiring | Sep 1997 | A |
5670329 | Oberhardt | Sep 1997 | A |
5674276 | Andersen et al. | Oct 1997 | A |
5688269 | Newton et al. | Nov 1997 | A |
5695457 | St. Goar et al. | Dec 1997 | A |
5697967 | Dinh et al. | Dec 1997 | A |
5702432 | Chen et al. | Dec 1997 | A |
5705293 | Hobson | Jan 1998 | A |
5728089 | Lal et al. | Mar 1998 | A |
5737279 | Carter | Apr 1998 | A |
5758298 | Guldner | May 1998 | A |
5782798 | Rise | Jul 1998 | A |
5804563 | Still et al. | Sep 1998 | A |
5807395 | Mulier et al. | Sep 1998 | A |
5819736 | Avny et al. | Oct 1998 | A |
5827190 | Palcic et al. | Oct 1998 | A |
5830179 | Mikus et al. | Nov 1998 | A |
5830207 | Leeb et al. | Nov 1998 | A |
5831012 | Nilsson et al. | Nov 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5843139 | Goedeke et al. | Dec 1998 | A |
5855801 | Lin et al. | Jan 1999 | A |
5873835 | Hastings et al. | Feb 1999 | A |
5908027 | Butterfield et al. | Jun 1999 | A |
5921982 | Lesh et al. | Jul 1999 | A |
5947119 | Reznick | Sep 1999 | A |
5954675 | Dellagatta | Sep 1999 | A |
5964773 | Greenstein | Oct 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6019729 | Itoigawa et al. | Feb 2000 | A |
6022316 | Eppstein et al. | Feb 2000 | A |
6053873 | Govari et al. | Apr 2000 | A |
6086528 | Adair | Jul 2000 | A |
6108597 | Kirchner et al. | Aug 2000 | A |
6111520 | Allen et al. | Aug 2000 | A |
6128538 | Fischell et al. | Oct 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6149603 | Parker | Nov 2000 | A |
6159230 | Samuels | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6170488 | Spillman, Jr. et al. | Jan 2001 | B1 |
6175757 | Watkins et al. | Jan 2001 | B1 |
6179789 | Tu et al. | Jan 2001 | B1 |
6185452 | Schulman et al. | Feb 2001 | B1 |
6186986 | Berg et al. | Feb 2001 | B1 |
6187599 | Asher et al. | Feb 2001 | B1 |
6197013 | Reed et al. | Mar 2001 | B1 |
6219577 | Brown, III et al. | Apr 2001 | B1 |
6221099 | Andersen et al. | Apr 2001 | B1 |
6240312 | Alfano et al. | May 2001 | B1 |
6240316 | Richmond et al. | May 2001 | B1 |
6248345 | Goldenheim et al. | Jun 2001 | B1 |
6249076 | Madden et al. | Jun 2001 | B1 |
6255361 | Rajagopalan et al. | Jul 2001 | B1 |
6255793 | Peless et al. | Jul 2001 | B1 |
6263245 | Snell | Jul 2001 | B1 |
6278379 | Allen et al. | Aug 2001 | B1 |
6289270 | Baumgarten | Sep 2001 | B1 |
6295990 | Lewis et al. | Oct 2001 | B1 |
6296638 | Davison et al. | Oct 2001 | B1 |
6322532 | D'Sa et al. | Nov 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6372248 | Qin et al. | Apr 2002 | B1 |
6383162 | Sugarbaker | May 2002 | B1 |
6384741 | O'Leary, Sr. | May 2002 | B1 |
6385472 | Hall et al. | May 2002 | B1 |
6398280 | Parker et al. | Jun 2002 | B1 |
6402678 | Fischell et al. | Jun 2002 | B1 |
6409674 | Brockway et al. | Jun 2002 | B1 |
6417641 | Peless et al. | Jul 2002 | B2 |
6436120 | Meglin | Aug 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6450937 | Mercereau et al. | Sep 2002 | B1 |
6453199 | Kobozev | Sep 2002 | B1 |
6464687 | Ishikawa et al. | Oct 2002 | B1 |
6475639 | Shahinpoor et al. | Nov 2002 | B2 |
6490483 | Willis | Dec 2002 | B2 |
6493607 | Bourne et al. | Dec 2002 | B1 |
6497714 | Ishikawa et al. | Dec 2002 | B1 |
6500174 | Maguire et al. | Dec 2002 | B1 |
6512949 | Combs et al. | Jan 2003 | B1 |
6512950 | Li et al. | Jan 2003 | B2 |
6514237 | Maseda | Feb 2003 | B1 |
6530950 | Alvarado et al. | Mar 2003 | B1 |
6547723 | Ouchi | Apr 2003 | B1 |
6547825 | Shimizu et al. | Apr 2003 | B1 |
6548982 | Papanikolopoulos et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6575969 | Rittman, III et al. | Jun 2003 | B1 |
6585763 | Keilman et al. | Jul 2003 | B1 |
6591137 | Fischell et al. | Jul 2003 | B1 |
6592567 | Levin et al. | Jul 2003 | B1 |
6597954 | Pless et al. | Jul 2003 | B1 |
6607553 | Healy et al. | Aug 2003 | B1 |
6612982 | Ouchi | Sep 2003 | B1 |
6616676 | Bashiri et al. | Sep 2003 | B2 |
6623519 | Edwin et al. | Sep 2003 | B2 |
6632216 | Houzego et al. | Oct 2003 | B2 |
6638273 | Farley et al. | Oct 2003 | B1 |
6648908 | Dobak, III et al. | Nov 2003 | B2 |
6666860 | Takahashi | Dec 2003 | B1 |
6669683 | Santini, Jr. et al. | Dec 2003 | B2 |
6673042 | Samson et al. | Jan 2004 | B1 |
6673363 | Luo et al. | Jan 2004 | B2 |
6679893 | Tran | Jan 2004 | B1 |
6709388 | Mosse et al. | Mar 2004 | B1 |
6711423 | Colvin, Jr. | Mar 2004 | B2 |
6712835 | Mazzocchi et al. | Mar 2004 | B2 |
6719684 | Kim et al. | Apr 2004 | B2 |
6735474 | Loeb et al. | May 2004 | B1 |
6735475 | Whitehurst et al. | May 2004 | B1 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6754536 | Swoyer et al. | Jun 2004 | B2 |
6755802 | Bell | Jun 2004 | B2 |
6755803 | Le et al. | Jun 2004 | B1 |
6764441 | Chiel et al. | Jul 2004 | B2 |
6773429 | Sheppard, Jr. et al. | Aug 2004 | B2 |
6776165 | Jin | Aug 2004 | B2 |
6797522 | Still et al. | Sep 2004 | B1 |
6802811 | Slepian | Oct 2004 | B1 |
6816632 | Slice | Nov 2004 | B1 |
6824508 | Kim et al. | Nov 2004 | B2 |
6824510 | Kim et al. | Nov 2004 | B2 |
6824561 | Soykan et al. | Nov 2004 | B2 |
6834118 | Kim | Dec 2004 | B2 |
6849183 | Gorsuch et al. | Feb 2005 | B2 |
6855115 | Fonseca et al. | Feb 2005 | B2 |
6860867 | Seward et al. | Mar 2005 | B2 |
6861001 | Lee et al. | Mar 2005 | B2 |
6866626 | Long et al. | Mar 2005 | B2 |
6875209 | Zvuloni et al. | Apr 2005 | B2 |
6889091 | Hine et al. | May 2005 | B2 |
6890303 | Fitz | May 2005 | B2 |
6898464 | Edell et al. | May 2005 | B2 |
6911004 | Kim et al. | Jun 2005 | B2 |
6911496 | Rhee et al. | Jun 2005 | B2 |
6920359 | Meadows et al. | Jul 2005 | B2 |
6921413 | Mahadevan-Jansen et al. | Jul 2005 | B2 |
6925357 | Wang et al. | Aug 2005 | B2 |
6929636 | Von Alten | Aug 2005 | B1 |
6936003 | Iddan | Aug 2005 | B2 |
6939290 | Iddan | Sep 2005 | B2 |
6939376 | Shulze et al. | Sep 2005 | B2 |
6950707 | Whitehurst | Sep 2005 | B2 |
6953589 | Trautman et al. | Oct 2005 | B1 |
6958034 | Iddan | Oct 2005 | B2 |
6959215 | Gliner et al. | Oct 2005 | B2 |
6960227 | Jones et al. | Nov 2005 | B2 |
6963792 | Green | Nov 2005 | B1 |
6984205 | Gazdzinski | Jan 2006 | B2 |
6984952 | Peless et al. | Jan 2006 | B2 |
6991617 | Hektner et al. | Jan 2006 | B2 |
7003352 | Whitehurst | Feb 2006 | B1 |
7013177 | Whitehurst et al. | Mar 2006 | B1 |
7020231 | Frey et al. | Mar 2006 | B1 |
7027134 | Garcia-Rubio et al. | Apr 2006 | B1 |
7037343 | Imran | May 2006 | B2 |
7039453 | Mullick et al. | May 2006 | B2 |
7042184 | Oleynikov et al. | May 2006 | B2 |
RE39133 | Clayton et al. | Jun 2006 | E |
7083578 | Lewkowicz et al. | Aug 2006 | B2 |
7101386 | Dobak, III | Sep 2006 | B2 |
7115109 | Gerdts et al. | Oct 2006 | B2 |
7118531 | Krill | Oct 2006 | B2 |
7125382 | Zhou et al. | Oct 2006 | B2 |
7131979 | DiCarlo et al. | Nov 2006 | B2 |
7160258 | Imran et al. | Jan 2007 | B2 |
7171285 | Kim et al. | Jan 2007 | B2 |
7181261 | Silver et al. | Feb 2007 | B2 |
7212110 | Martin et al. | May 2007 | B1 |
7214182 | Shimizu et al. | May 2007 | B2 |
7228162 | Ward et al. | Jun 2007 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7245954 | Glukhovsky | Jul 2007 | B2 |
7297113 | Russell et al. | Nov 2007 | B1 |
7341577 | Gill | Mar 2008 | B2 |
7365509 | Park et al. | Apr 2008 | B2 |
7365614 | McCorquodale et al. | Apr 2008 | B2 |
7383071 | Russell et al. | Jun 2008 | B1 |
7398734 | Jean | Jul 2008 | B1 |
7451537 | Liu et al. | Nov 2008 | B2 |
7486967 | Pan et al. | Feb 2009 | B2 |
7572228 | Wolinsky et al. | Aug 2009 | B2 |
7596403 | Horn | Sep 2009 | B2 |
7625338 | Gilad et al. | Dec 2009 | B2 |
7684840 | Palti | Mar 2010 | B2 |
7713196 | Baker, Jr. | May 2010 | B2 |
7736300 | Ziegler et al. | Jun 2010 | B2 |
7744542 | Piaget et al. | Jun 2010 | B2 |
7801626 | Moser | Sep 2010 | B2 |
7840271 | Kieval et al. | Nov 2010 | B2 |
7857767 | Ferren et al. | Dec 2010 | B2 |
20010029348 | Willis | Oct 2001 | A1 |
20010051766 | Gazdzinski | Dec 2001 | A1 |
20020065509 | Lebel et al. | May 2002 | A1 |
20020068080 | Lerner | Jun 2002 | A1 |
20020090388 | Humes et al. | Jul 2002 | A1 |
20020103417 | Gazdzinski | Aug 2002 | A1 |
20020116029 | Miller et al. | Aug 2002 | A1 |
20020116034 | Miller et al. | Aug 2002 | A1 |
20020147480 | Mamayek | Oct 2002 | A1 |
20020156462 | Stultz | Oct 2002 | A1 |
20020165592 | Glukhovsky et al. | Nov 2002 | A1 |
20020169436 | Gurm et al. | Nov 2002 | A1 |
20020171385 | Kim et al. | Nov 2002 | A1 |
20020188323 | Penner et al. | Dec 2002 | A1 |
20020193679 | Malave et al. | Dec 2002 | A1 |
20020193874 | Crowley | Dec 2002 | A1 |
20020198470 | Imran et al. | Dec 2002 | A1 |
20020198521 | Maguire | Dec 2002 | A1 |
20020198604 | Schulman et al. | Dec 2002 | A1 |
20030024534 | Silvestri et al. | Feb 2003 | A1 |
20030040704 | Dorros et al. | Feb 2003 | A1 |
20030060723 | Joo et al. | Mar 2003 | A1 |
20030065250 | Chiel et al. | Apr 2003 | A1 |
20030065358 | Frecker et al. | Apr 2003 | A1 |
20030069475 | Banik et al. | Apr 2003 | A1 |
20030069523 | Williams et al. | Apr 2003 | A1 |
20030093031 | Long et al. | May 2003 | A1 |
20030151524 | Clark | Aug 2003 | A1 |
20030152823 | Heller | Aug 2003 | A1 |
20030153866 | Long et al. | Aug 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
20030163177 | Eggers et al. | Aug 2003 | A1 |
20030167000 | Mullick et al. | Sep 2003 | A1 |
20030191430 | D'Andrea et al. | Oct 2003 | A1 |
20030214579 | Iddan | Nov 2003 | A1 |
20030214580 | Iddan | Nov 2003 | A1 |
20030220556 | Porat et al. | Nov 2003 | A1 |
20040008853 | Pelrine et al. | Jan 2004 | A1 |
20040018508 | Friedman | Jan 2004 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040064093 | Hektner et al. | Apr 2004 | A1 |
20040073177 | Hickle | Apr 2004 | A1 |
20040073190 | Deem et al. | Apr 2004 | A1 |
20040092825 | Madar et al. | May 2004 | A1 |
20040097819 | Duarte | May 2004 | A1 |
20040098030 | Makower et al. | May 2004 | A1 |
20040111019 | Long | Jun 2004 | A1 |
20040133147 | Woo | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040147939 | Rabkin et al. | Jul 2004 | A1 |
20040148034 | Kagan et al. | Jul 2004 | A1 |
20040152988 | Weirich | Aug 2004 | A1 |
20040162469 | Imran | Aug 2004 | A1 |
20040162501 | Imran | Aug 2004 | A1 |
20040176664 | Iddan | Sep 2004 | A1 |
20040193010 | Fujimori et al. | Sep 2004 | A1 |
20040199246 | Chu et al. | Oct 2004 | A1 |
20040225325 | Bonutti | Nov 2004 | A1 |
20040225326 | Weiner et al. | Nov 2004 | A1 |
20040260391 | Santini, Jr. et al. | Dec 2004 | A1 |
20040267240 | Gross et al. | Dec 2004 | A1 |
20050004474 | Iddan | Jan 2005 | A1 |
20050004553 | Douk | Jan 2005 | A1 |
20050021023 | Guglielmi et al. | Jan 2005 | A1 |
20050027236 | Douk | Feb 2005 | A1 |
20050043583 | Killmann et al. | Feb 2005 | A1 |
20050058701 | Gross et al. | Mar 2005 | A1 |
20050062562 | Ries | Mar 2005 | A1 |
20050065592 | Holzer | Mar 2005 | A1 |
20050069925 | Ford et al. | Mar 2005 | A1 |
20050079132 | Wang et al. | Apr 2005 | A1 |
20050107870 | Wang et al. | May 2005 | A1 |
20050113460 | Glick | May 2005 | A1 |
20050121411 | Cohen | Jun 2005 | A1 |
20050126916 | Lockard et al. | Jun 2005 | A1 |
20050149170 | Tassel et al. | Jul 2005 | A1 |
20050151524 | Sae-Ueng et al. | Jul 2005 | A1 |
20050171418 | Lin | Aug 2005 | A1 |
20050171434 | Madden et al. | Aug 2005 | A1 |
20050177223 | Palmaz | Aug 2005 | A1 |
20050182482 | Wang et al. | Aug 2005 | A1 |
20050203613 | Arney et al. | Sep 2005 | A1 |
20050215911 | Alfano et al. | Sep 2005 | A1 |
20050216074 | Sahatjian et al. | Sep 2005 | A1 |
20050221529 | Bang et al. | Oct 2005 | A1 |
20050228259 | Glukhovsky et al. | Oct 2005 | A1 |
20050234393 | Wood | Oct 2005 | A1 |
20050234440 | Wood | Oct 2005 | A1 |
20050238689 | Carpenter et al. | Oct 2005 | A1 |
20050272806 | Falotico et al. | Dec 2005 | A1 |
20050272974 | Iddan | Dec 2005 | A1 |
20050277839 | Alderman et al. | Dec 2005 | A1 |
20050278020 | Wang et al. | Dec 2005 | A1 |
20060004395 | Chiel et al. | Jan 2006 | A1 |
20060009810 | Mann et al. | Jan 2006 | A1 |
20060015146 | Girouard et al. | Jan 2006 | A1 |
20060037617 | Walke et al. | Feb 2006 | A1 |
20060042631 | Martin et al. | Mar 2006 | A1 |
20060074479 | Bailey et al. | Apr 2006 | A1 |
20060119304 | Farritor et al. | Jun 2006 | A1 |
20060152309 | Mintchev et al. | Jul 2006 | A1 |
20060167339 | Gilad et al. | Jul 2006 | A1 |
20060169294 | Kaler et al. | Aug 2006 | A1 |
20060235275 | Rabinovitz et al. | Oct 2006 | A1 |
20060252987 | Hasegawa et al. | Nov 2006 | A1 |
20070010868 | Ferren et al. | Jan 2007 | A1 |
20070066929 | Ferren et al. | Mar 2007 | A1 |
20070088334 | Hillis et al. | Apr 2007 | A1 |
20070156211 | Ferren et al. | Jul 2007 | A1 |
20070225634 | Ferren et al. | Sep 2007 | A1 |
20080063703 | Gross et al. | Mar 2008 | A1 |
20080066929 | Costa et al. | Mar 2008 | A1 |
20080103440 | Ferren et al. | May 2008 | A1 |
20080121054 | Goldenberg et al. | May 2008 | A1 |
20080241847 | Hoon et al. | Oct 2008 | A1 |
20080243056 | Hillis et al. | Oct 2008 | A1 |
20080266106 | Lim et al. | Oct 2008 | A1 |
20090062646 | Creighton, IV et al. | Mar 2009 | A1 |
20090069821 | Farritor et al. | Mar 2009 | A1 |
20090082652 | Koh et al. | Mar 2009 | A1 |
20090182388 | Von Arx et al. | Jul 2009 | A1 |
Number | Date | Country |
---|---|---|
99810271.7 | Oct 2001 | CN |
1 245 201 | Oct 2002 | EP |
1 618 831 | Jan 2006 | EP |
2 163 206 | Mar 2010 | EP |
2001-506871 | Mar 1998 | JP |
2002-153569 | May 2002 | JP |
2005-74229 | Mar 2005 | JP |
WO 9639999 | Dec 1996 | WO |
WO 9809582 | Mar 1998 | WO |
WO 9814243 | Apr 1998 | WO |
WO 9920335 | Apr 1999 | WO |
WO 9944665 | Sep 1999 | WO |
WO 0069515 | Nov 2000 | WO |
WO 0108548 | Feb 2001 | WO |
WO 0124731 | Apr 2001 | WO |
WO 03072157 | Sep 2003 | WO |
WO 03090618 | Nov 2003 | WO |
WO 03106966 | Dec 2003 | WO |
WO 2004028335 | Apr 2004 | WO |
WO 2004058041 | Jul 2004 | WO |
WO 2004086958 | Oct 2004 | WO |
WO 2005082248 | Sep 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20060069425 A1 | Mar 2006 | US |